Verdict No. 3007 · Search date 2026-09-07 · Methodology v0.9
Buteyko breathing training added to adult asthma care,
does it really help with Reduced symptoms and rescue bronchodilator use?
30-Second Summary
C
Evidence Grade C · 50 · Safety caution
Limited Buteyko symptom and rescue-use signals do not establish better lung function or replace inhaled therapy
Do not independently reduce or stop prescribed inhalers, especially inhaled corticosteroids. During an acute asthma attack, breathing exercises must not replace a rescue inhaler or emergency care; medication changes require a clinician-supervised asthma plan.
What the
research showsGrade C with 50 points. A 90-person three-arm trial had a positive symptom co-primary and some trials reported less rescue use or better quality of life, while the paired airway-responsiveness outcome and asthma control versus active breathing education were null. This is limited adjunctive evidence, not support for replacing inhaled treatment or preventing exacerbations.
research showsGrade C with 50 points. A 90-person three-arm trial had a positive symptom co-primary and some trials reported less rescue use or better quality of life, while the paired airway-responsiveness outcome and asthma control versus active breathing education were null. This is limited adjunctive evidence, not support for replacing inhaled treatment or preventing exacerbations.
What the
ads claimClaims that breathing retraining cures asthma or lets people stop inhalers extend limited symptom results to null lung-function and exacerbation outcomes.
ads claimClaims that breathing retraining cures asthma or lets people stop inhalers extend limited symptom results to null lung-function and exacerbation outcomes.
Useful facts when choosing a product
- The evidence concerns an adjunct to standard inhaled care.
- Medication reduction used clinical review rather than unsupervised withdrawal.
- General breathing retraining and pranayama were not pooled as Buteyko effects.
Gap Measurement · Verdict 3007 · C 50
What the research actually shows
Buteyko education was compared with asthma education, a sham device, or active pranayama. Medication reduction was medically reviewed, and objective lung function and exacerbations were assessed separately.
Why this is classified as C (50)
The symptom co-primary is a strength, but independently funded replication is unverified; split co-primary results, lack of masking, 23% attrition, and null objective outcomes give C with 50 points.
Counterpoint. Null FEV1, PEF, PD20, FeNO, and exacerbation findings prevent translating symptom signals into improved airway physiology or exacerbation prevention.
Rejudgment record. Cross-check applied — Read the positive symptom co-primary alongside null PD20 and null control versus active breathing education; incorporated unverified independent funding, 23% attrition, and taper safeguards
Scoring profile behind this grade
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | E+ | Meets the clinically important threshold |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced asthma symptoms and rescue bronchodilator use | C | Several small trials signal benefit, limited by masking and endpoint selection. |
| Improved FEV1, PEF, or airway responsiveness | D | Direct trials repeatedly failed to show improvement. |
| Prevention of exacerbations or replacement of inhaled therapy | D | Exacerbations did not improve and reductions were clinically supervised. |
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Study 1 | Blinded randomized controlled trial | 39 | Specific funding and conflicts unverified | Beta2-agonist and ICS use, QOL, FEV1 and PEF | Median beta2-agonist reduction 904 versus 57 mcg, P=.002; FEV1 and PEF null; ICS P=.06 and QOL P=.09 | Early direct trial |
| Study 2 | Three-arm randomized Buteyko, pranayama, and placebo trial | 69 | Specific funding and conflicts unverified | Symptoms and rescue use; PD20, FEV1, exacerbations, and ICS | Median symptom change -3 versus -1 versus 0, P=.003; bronchodilator -2 puffs/day, P=.005; objective outcomes, exacerbations, and ICS null | Key trial with active control |
| Study 3 | Randomized Buteyko versus physiotherapist-led breathing education trial | 6 | Anonymous donor; independence unverified | Six-month asthma-control primary and ICS-reduction secondary | Control 79% versus 72%, P=.4; missing-as-failure 68% versus 70%, P=.7; ICS reduction 23/56 versus 13/63, P=.02 | Key contrary active-education control |
| Study 4 | Randomized Buteyko versus usual-care trial | 60 | Reported public or institutional support; full conflicts cross-checked | Primary voluntary control pause; secondary ACQ and medication; FEV1 and FeNO | Primary and some secondary signals; FEV1 and FeNO null, registered after recruitment began | Modern supporting trial |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-09-07).
Bowler SD, Green A, Mitchell CA. Buteyko breathing techniques in asthma: a blinded randomised controlled trial. Med J Aust. 1998;169:575-578. PMID: 9887897. DOI: 10.5694/j.1326-5377.1998.tb123422.x.
checkedCooper S, Oborne J, Newton S, et al. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial. Thorax. 2003;58:674-679. PMID: 12885982. PMCID: PMC1746772. DOI: 10.1136/thorax.58.8.674.
checkedCowie RL, Conley DP, Underwood MF, Reader PG. A randomised controlled trial of the Buteyko technique as an adjunct to conventional management of asthma. Respir Med. 2008;102:726-732. PMID: 18249107. DOI: 10.1016/j.rmed.2007.12.012.
checkedVagedes K, et al. Buteyko breathing technique for asthma: an effective intervention. Eur J Med Res. 2024;29:42. PMID: 38212823. PMCID: PMC10782792. DOI: 10.1186/s40001-023-01634-1. NCT03098849.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-07 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-07 · Corrections: none
Cite this verdict
[Chamgap] Buteyko Breathing for Adult Asthma—Separate Symptom and Rescue-Medication Signals From Null Lung Function — Evidence Grade C·50. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/buteyko-breathing-adult-asthma-symptoms-medication-lung-function/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.